Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
38.3M
-
Number of holders
-
105
-
Total 13F shares, excl. options
-
29.6M
-
Shares change
-
-653K
-
Total reported value, excl. options
-
$199M
-
Value change
-
-$4.88M
-
Put/Call ratio
-
0
-
Number of buys
-
66
-
Number of sells
-
-48
-
Price
-
$6.72
Significant Holders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) as of Q2 2025
134 filings reported holding TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2025.
Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) has 105 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.6M shares
of 38.3M outstanding shares and own 77.15% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (4.87M shares), MPM ASSET MANAGEMENT LLC (4.38M shares), 5AM Venture Management, LLC (4.31M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.57M shares), BlackRock, Inc. (2.02M shares), VANGUARD GROUP INC (1.6M shares), JANUS HENDERSON GROUP PLC (1.52M shares), WELLINGTON MANAGEMENT GROUP LLP (1.06M shares), StepStone Group LP (761K shares), and GEODE CAPITAL MANAGEMENT, LLC (632K shares).
This table shows the top 105 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.